Listed

Kiora Pharmaceuticals Inc: Form 10-Q for the period ended Sep 30, 2016

Filed with the SEC on Nov 1, 2016 and accepted by EDGAR at Nov 1, 2016, 17:12 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2016-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2016-07-01 to 2016-09-30$274.3kus-gaap:SalesRevenueNet
Revenue9 months2016-01-01 to 2016-09-30$508.9kus-gaap:SalesRevenueNet
Research and development3 months2016-07-01 to 2016-09-30$2.4mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2016-01-01 to 2016-09-30$5.8mus-gaap:ResearchAndDevelopmentExpense
Interest expense3 months2016-07-01 to 2016-09-30$0us-gaap:InterestExpense
Interest expense9 months2016-01-01 to 2016-09-30$0us-gaap:InterestExpense
Net income3 months2016-07-01 to 2016-09-30−$3.4mus-gaap:ProfitLoss
Net income9 months2016-01-01 to 2016-09-30−$9.6mus-gaap:ProfitLoss
Diluted EPS3 months2016-07-01 to 2016-09-30−$0.36us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS9 months2016-01-01 to 2016-09-30−$1.13us-gaap:EarningsPerShareBasicAndDiluted
Cash and equivalentsAt period end2016-09-30$5.7mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2016-09-30$6.3mus-gaap:AssetsCurrent
Total assetsAt period end2016-09-30$10.6mus-gaap:Assets
Current liabilitiesAt period end2016-09-30$6.2mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2016-09-30$7.4mus-gaap:Liabilities
Shareholders' equityAt period end2016-09-30$3.2mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001144204-16-130888. Last ingested by Listed: Nov 12, 2026, 17:43 ET. Listed shows no prices and gives no investment advice.